Search Results 21-30 of 16531 for Progressive supranuclear palsy
The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale ( ...
Researchers discover new molecular drug targets for progressive neurological disorder ... Progressive supranuclear palsy (PSP) is an uncurable brain disorder ...
The primary objective of this study is to asssess the safety and tolerability of TPN-101 in patients with progressive supranuclear palsy (PSP). Participation ...
The purpose of this study is to assess the long-term safety and effectiveness of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
Those with progressive supranuclear palsy typically have eye movement abnormalities. They also have gait instability with falls early in the disease. People ...
Clinical Trials · A Study to Assess the Effectiveness, Safety, Tolerability, and Drug/Body Interactions of ABBV-8E12 in Progressive Supranuclear Palsy · More ...
... Progressive Supranuclear Palsy (PSP) participants when administered intrathecally once every 4 weeks (four administrations) in a range of escalating doses.
Progressive supranuclear palsy. This is a rare nervous system condition that causes problems with walking, balance and eye movements. It may resemble ...
Breast cancer / progressive supra nuclear palsy / esophageal cancer. 00:00. |. Breast cancer / progressive supranuclear palsy / esophageal cancer. Oct. 31, 2020.
... progressive supranuclear palsy and characterization of amphiphysin-IgG autoimmunity ... The clinical diagnosis of progressive supranuclear palsy (PSP) can be ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.